JP2015506355A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506355A5
JP2015506355A5 JP2014549480A JP2014549480A JP2015506355A5 JP 2015506355 A5 JP2015506355 A5 JP 2015506355A5 JP 2014549480 A JP2014549480 A JP 2014549480A JP 2014549480 A JP2014549480 A JP 2014549480A JP 2015506355 A5 JP2015506355 A5 JP 2015506355A5
Authority
JP
Japan
Prior art keywords
alkyl
group
heterocyclyl
substituted
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014549480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506355A (ja
JP6130399B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/077027 external-priority patent/WO2013098375A1/en
Publication of JP2015506355A publication Critical patent/JP2015506355A/ja
Publication of JP2015506355A5 publication Critical patent/JP2015506355A5/ja
Application granted granted Critical
Publication of JP6130399B2 publication Critical patent/JP6130399B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014549480A 2011-12-30 2012-12-28 新規アゼチジン誘導体、医薬組成物およびそれらの使用 Expired - Fee Related JP6130399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11196170.2 2011-12-30
EP11196170 2011-12-30
PCT/EP2012/077027 WO2013098375A1 (en) 2011-12-30 2012-12-28 New azetidine derivatives, pharmaceutical compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2015506355A JP2015506355A (ja) 2015-03-02
JP2015506355A5 true JP2015506355A5 (enExample) 2016-02-25
JP6130399B2 JP6130399B2 (ja) 2017-05-17

Family

ID=47553036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549480A Expired - Fee Related JP6130399B2 (ja) 2011-12-30 2012-12-28 新規アゼチジン誘導体、医薬組成物およびそれらの使用

Country Status (13)

Country Link
US (1) US8623860B2 (enExample)
EP (1) EP2797884B1 (enExample)
JP (1) JP6130399B2 (enExample)
KR (1) KR20140115307A (enExample)
CN (1) CN104093705A (enExample)
AU (1) AU2012360797A1 (enExample)
BR (1) BR112014015845A8 (enExample)
CA (1) CA2861013A1 (enExample)
EA (1) EA201400771A1 (enExample)
IL (1) IL232914A0 (enExample)
MX (1) MX2014007897A (enExample)
PH (1) PH12014501514A1 (enExample)
WO (1) WO2013098375A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012253653A1 (en) 2011-05-10 2013-05-02 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (enExample) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
WO2014061693A1 (ja) * 2012-10-17 2014-04-24 塩野義製薬株式会社 新規非芳香族炭素環又は非芳香族複素環誘導体
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
CN103483273B (zh) * 2013-09-12 2015-11-25 浙江工业大学 6-甲基-5-氟-2,4-嘧啶二胺类化合物及其制备与应用
JPWO2015056782A1 (ja) 2013-10-17 2017-03-09 塩野義製薬株式会社 新規アルキレン誘導体
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
AU2015229188A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3157917B1 (en) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2016105484A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105468A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
WO2017062581A1 (en) 2015-10-06 2017-04-13 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
US10662207B2 (en) 2016-04-07 2020-05-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
US10899751B2 (en) 2016-06-21 2021-01-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
CN110776504B (zh) * 2019-11-29 2021-07-30 扬州工业职业技术学院 一种苯异噁唑乙氧基环丁胺衍生物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
DE102005055726A1 (de) 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP1976848A2 (en) 2005-12-21 2008-10-08 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
CA2654792A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2350054A4 (en) 2008-10-17 2012-03-28 Merck Canada Inc AZETIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE
WO2010127212A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
CN103025716B (zh) 2010-04-27 2014-12-24 武田药品工业株式会社 二环化合物衍生物及其作为acc抑制剂的用途
NZ603876A (en) * 2010-05-13 2015-02-27 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors

Similar Documents

Publication Publication Date Title
CN105745206B (zh) 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
JP6648137B2 (ja) ヘテロ環式誘導体およびその使用
EP3083639B1 (en) Cyclic sulfone and sulfoximine analogs and uses thereof
JP4794446B2 (ja) イソキノリン系カリウムチャンネル阻害薬
RU2013149174A (ru) Новое имидазооксазиновое соединение или его соль
JP2015500856A5 (enExample)
AU2012361581B2 (en) Effect potentiator for antitumor agents
RU2012104700A (ru) Азабициклосоединение и его соль
RU2012129168A (ru) Производные оксазина
JP2015503540A5 (enExample)
RS54339B1 (sr) Novi antimalarijski agensi
JP2016512558A (ja) ヒト免疫不全ウイルス複製の阻害剤
CA2734415A1 (en) Picolinamide derivatives as kinase inhibitors
JP2013509392A5 (enExample)
RU2002131885A (ru) Антраниламиды и их применение в качестве лекарственных средств
RU2012108423A (ru) Ацилгуанидиновые производные с азотсодержащим циклом
JP2014516070A5 (enExample)
AU2009335221A1 (en) Toluidine sulfonamides and their use
JP7203846B2 (ja) 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
JP2013540714A5 (enExample)
JP2015502371A5 (enExample)
JP2015500267A5 (enExample)
CN105367582B (zh) 银杏内酯b衍生物及其在药物中的应用
MX2013012577A (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
Cunico et al. Synthesis and anti-mycobacterial activity of novel amino alcohol derivatives